Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
Metastatic Prostate Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 152 (planned)
- Started
- Jun 3, 2026
- Main results expected
- Sep 25, 2029
- Fully finished
- Sep 25, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part A: Number of participants with treatment-emergent adverse events (TEAEs)including serious adverse events (SAEs), treatment-related AEs (TRAEs) and adverse events of special interests (AESIs)
Measured over: Up to approximately 1 year after last dose
Part A: Number of participants with dose limiting toxicities (DLTs)
Measured over: From date of first dose up to approximately 2 cycles (up to 3 months)
Part B: Number of participants with TEAEs
Measured over: Up to approximately 1 year after last dose
Part B: Prostate Specific Antigen 50 (PSA50) response rate
Measured over: Up to 3 years 4 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07590934 · record last updated 2026-10-14 · checked 2026-11-09 15:47 UTC